The announcement follows the decision to discontinue the COAST and ShORe trials in wet age-related macular degeneration after ...

Opthea’s staff are paying for its clinical failures. Days after back-to-back flops sank an eye disease asset, the biotech ...

In the wake of failed late-stage clinical trials last month for its novel retinal disease therapy, Melbourne-headquartered ...

Regal Partners has written off its entire investment in Opthea, which contributed to funds under management (FUM) taking an 8.3% hit in the March 2025 quarter.

Fintel reports that on April 7, 2025, BELL POTTER SECURITIES downgraded their outlook for Opthea (OTCPK:CKDXF) from Buy to ...

Shares drop 1.8pc at the closing bell after US imposes 104pc China tariff; Treasuries sell-off; RBNZ cuts rates by 25bps; oil ...

Fintel reports that on April 7, 2025, BELL POTTER SECURITIES downgraded their outlook for Opthea Limited - Depositary Receipt ...

Shares drop, US closes in on 104pc China tariff; RBNZ signals scope for further cuts; oil below $US61; iron ore at ...

A broker says this ASX biotech share potentially 'has no value from here', and reiterates the importance of diversification ...